<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211740</url>
  </required_header>
  <id_info>
    <org_study_id>OCH-NCNP1-02</org_study_id>
    <nct_id>NCT04211740</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial of OCH-NCNP1</brief_title>
  <official_title>Efficacy and Safety of OCH-NCNP1 in Patients With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center of Neurology and Psychiatry, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center of Neurology and Psychiatry, Japan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the efficacy and safety of OCH-NCNP1 compared to placebo in&#xD;
      subjects diagnosed with relapsing remitting multiple sclerosis (RRMS) and secondary&#xD;
      progressive mltiple sclerosis (SPMS) .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of the patients who identified new or enlarging T2 lesions on MRI scans compared to baseline</measure>
    <time_frame>Change from screening at Month 6.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>annual relapse rate</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of asymptomatic</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) / Functional Scale (FS)</measure>
    <time_frame>screening, 4weeks, 8 weeks, 12 weeks, 16weeks, 20 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of sustained reduction in disability (SRD)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of MRI</measure>
    <time_frame>Change from screening at Month 3 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of No evidence of disease activity (NEDA)</measure>
    <time_frame>Change from screening at Month 3 and 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>OCH-NCNP1 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCH-NCNP1</intervention_name>
    <description>OCH-NCNP1 3mg is supplied as granules and take orally once a week.</description>
    <arm_group_label>OCH-NCNP1 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is supplied as granules and take orally once a week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject with Multiple Sclerosis eligible for enrolment in the study must meet all of&#xD;
             the following criteria:&#xD;
&#xD;
               1. Provision of written informed consent to participate in this study&#xD;
&#xD;
               2. Patients diagnosed as relapsing remitting multiple sclerosis based on modified&#xD;
                  McDonald criteria in 2017&#xD;
&#xD;
               3. Relape must have been confirmed by a neurologist at least twice within 24 months,&#xD;
                  or once within 12 months before enrollment&#xD;
&#xD;
               4. Have at least one T2 lesion on MRI scans at screening&#xD;
&#xD;
               5. EDSS less than or equal to 7&#xD;
&#xD;
               6. 20 =&lt; Age &lt; 65&#xD;
&#xD;
               7. Promise to prevent conception for at least 90 days after the last administration&#xD;
&#xD;
               8. Neurological stability has been confirmed by a neurologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with MS patients meeting any of the following criteria must not be enrolled in&#xD;
             the study:&#xD;
&#xD;
               1. Diagnosed as Neuromyelitis Optica&#xD;
&#xD;
               2. Women who are pregnant or lactating&#xD;
&#xD;
               3. Patients who is prohibited MRI&#xD;
&#xD;
               4. Patients who are allergic to Gd-contrast medium&#xD;
&#xD;
               5. History of liver diseases or liver transplantation&#xD;
&#xD;
               6. Liver dysfunction in the screening test and baseline physical examination&#xD;
&#xD;
               7. History of cancer past five years&#xD;
&#xD;
               8. Negative for herpes zoster virus antibody&#xD;
&#xD;
               9. Positive for Syphilis serum reaction&#xD;
&#xD;
              10. Positive for Beta-glucan or positive for T-spot&#xD;
&#xD;
              11. Positive for Anti-Aquaporin 4 antibody&#xD;
&#xD;
              12. History of HIV infection&#xD;
&#xD;
              13. History of HBV or HCV infection&#xD;
&#xD;
              14. History of Transplantation&#xD;
&#xD;
              15. Use of any other investigational agents and/or experimental agents within 4&#xD;
                  months prior to the first anticipated administration of study medication.&#xD;
&#xD;
              16. History of blood donation (200 ml within 2 months, 400 ml within 3 months) prior&#xD;
                  to the first anticipated administration of study medication&#xD;
&#xD;
              17. Lymphocyte number &lt; 600 /mm3 in peripheral blood&#xD;
&#xD;
              18. Current diagnosed or suspected infectious diseases&#xD;
&#xD;
              19. Compromised Patients&#xD;
&#xD;
              20. Inflammatory Bowel disease&#xD;
&#xD;
              21. Subjects with prolongation of QT/QTc interval&#xD;
&#xD;
              22. History or have risk of torsade de pointes&#xD;
&#xD;
              23. Taking the medicine which has risk of prolongation of QT/QTc interval&#xD;
&#xD;
              24. History of severe allergy of medicine or food&#xD;
&#xD;
              25. History or current of drug/ alcohol addiction&#xD;
&#xD;
              26. Bronchial Asthma&#xD;
&#xD;
              27. Epilepsy Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomoko Okamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Center of Neurology and Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Center of Neurology and Psychiatry, Japan</investigator_affiliation>
    <investigator_full_name>Tomoko Okamoto</investigator_full_name>
    <investigator_title>Medical director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

